Status:
UNKNOWN
Decitabine + BUCY vs BUCY Conditioning Regimen for Myeloid Tumors Undergoing Allo-HSCT
Lead Sponsor:
Nanfang Hospital, Southern Medical University
Collaborating Sponsors:
Peking University People's Hospital
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Conditions:
Allogeneic Hematopoietic Stem Cell Transplantation
Conditioning
Eligibility:
All Genders
14-65 years
Phase:
PHASE2
PHASE3
Brief Summary
Recent studies have demonstrated that allogeneic hematopoietic stem cell transplantation (allo-HSCT) could be a valuable treatment choice for myeloid tumors, such as acute myeloid leukemia and myelody...
Detailed Description
Recent studies have demonstrated that allogeneic hematopoietic stem cell transplantation (allo-HSCT) could be a valuable treatment choice for myeloid tumors, such as acute myeloid leukemia and myelody...
Eligibility Criteria
Inclusion
- Myeloid tumors undergoing allo-HSCT
- 14-65 years
Exclusion
- Any abnormality in a vital sign (e.g., heart rate, respiratory rate, or blood pressure)
- Patients with any conditions not suitable for the trial (investigators' decision)
Key Trial Info
Start Date :
September 1 2019
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
August 1 2023
Estimated Enrollment :
196 Patients enrolled
Trial Details
Trial ID
NCT04098653
Start Date
September 1 2019
End Date
August 1 2023
Last Update
September 23 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Hematology,Nanfang Hospital, Southern Medical University
Guangzhou, Guangdong, China, 510515